Fiste Oraianthi, Dimos Apostolos, Kardara Vasiliki-Elpida, Ballasis Konstantinos, Karampeazis Athanasios
Department of Medical Oncology, 401 General Military Hospital of Athens, Athens, GRC.
Department of Cardiology, 401 General Military Hospital of Athens, Athens, GRC.
Cureus. 2020 Dec 24;12(12):e12262. doi: 10.7759/cureus.12262.
Heart angiosarcoma, the most frequent among cardiac malignancies, is an extremely rare vascular tumor known to carry a dismal prognosis. The spectrum of presenting symptoms depends on tumor's size, its anatomic location, and its invasiveness, whereas imaging techniques including cardiac magnetic resonance are critical in the differential diagnosis between malignant and benign neoplasms. Despite there are various available systemic therapeutic regimens for advanced cardiac angiosarcomas, yet, it still remains unclear which of them offers the best survival outcome in general. We present the uncommon case of metastatic right atrium angiosarcoma in a young male patient, in which the combination of propranolol and weekly paclitaxel, as first-line treatment, showed promising activity with manageable toxicity. Given the existing strong rationale for repurposing propranolol in oncology, this therapeutic approach merits further investigation in prospective studies with heart angiosarcoma patients.
心脏血管肉瘤是心脏恶性肿瘤中最常见的一种，是一种极为罕见的血管肿瘤，预后极差。出现的症状范围取决于肿瘤的大小、解剖位置及其侵袭性，而包括心脏磁共振成像在内的成像技术对于鉴别恶性和良性肿瘤至关重要。尽管对于晚期心脏血管肉瘤有多种可用的全身治疗方案，但总体而言哪种方案能提供最佳生存结果仍不清楚。我们报告了一名年轻男性患者发生转移性右心房血管肉瘤的罕见病例，其中，普萘洛尔和每周一次的紫杉醇联合作为一线治疗，显示出有前景的活性且毒性可控。鉴于在肿瘤学中重新利用普萘洛尔有充分的现有理论依据，这种治疗方法值得在心脏血管肉瘤患者的前瞻性研究中进一步探索。
